Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.
about
Phosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADDARTS and Siah collaborate in a pathway for XIAP degradationApoptosis: targets in pancreatic cancerSMAC is expressed de novo in a subset of cervical cancer tumorsRecent Developments in Peptide-Based Nucleic Acid DeliveryStructure-Based Design, Synthesis, Evaluation, and Crystallographic Studies of Conformationally Constrained Smac Mimetics as Inhibitors of the X-linked Inhibitor of Apoptosis Protein (XIAP) †Potential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseasesCellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicityAn unconventional IAP-binding motif revealed by target-assisted iterative screening (TAIS) of the BIR3-cIAP1 domain.Reversal of hyperglycemia by protein transduction of NeuroD in vivo.Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataInducing death in tumor cells: roles of the inhibitor of apoptosis proteins.Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitroPositive cross-talk between estrogen receptor and NF-kappaB in breast cancer.HSF1 down-regulates XAF1 through transcriptional regulation.X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma.E3 ubiquitin ligases as cancer targets and biomarkers.Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cellsTargeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)Role of mitochondrial membrane permeabilization in apoptosis and cancer.Toxic proteins released from mitochondria in cell death.Death receptors in chemotherapy and cancer.The mitochondrial death pathway: a promising therapeutic target in diseasesApoptosis-based therapies and drug targets.Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cellsGrowth Hormone Mediates Its Protective Effect in Hepatic Apoptosis through Hnf6Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function.Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo.Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeuticsRole of Smac/DIABLO in cancer progression.Inhibitor of apoptosis proteins as targets for anticancer therapy.X-linked inhibitor of apoptosis protein as a therapeutic target.Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistanceDesign of small-molecule peptidic and nonpeptidic Smac mimetics.Two distinct signalling cascades target the NF-kappaB regulatory factor c-IAP1 for degradation.IAP proteins as targets for drug development in oncologyX-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer modelIAP-targeted therapies for cancer.
P2860
Q24301769-92B3A03C-884A-49A2-B14D-6CA05ABEEEB2Q24321222-D6FCC23E-198F-4CB1-9C46-C6B900D5FD4CQ24800170-BDDB1CF6-ECB7-4DE8-91F0-BA23539F6603Q24804096-F4944CE0-967E-446B-AC40-83B086C93502Q27487857-60321DC6-8026-4B46-A56F-C548A54A14E1Q27652682-1E9912A6-7119-4225-B7B5-79BBB39EFB73Q28391383-07D7CF68-BB37-41E3-A1D5-71C91A8F10F1Q28540934-54BD3F73-FC25-4375-8F05-D2FBAAEF03E8Q33263114-5AC6845D-2F75-4D9C-A166-7481ED751E28Q33291283-7F501619-D819-44E8-BE39-262AFCA1A19DQ33388617-B062E8FB-6816-459C-85DE-17208B880A37Q33632016-E7181261-2DEA-4FF8-8F02-C10C88CAC78DQ33841579-60F2B05D-D60C-4B3E-9730-4B4CD389EC58Q33961325-19CA9845-96B1-4676-B2D7-7156FD3D3CCAQ34374852-7B8F1859-EEC2-470B-A0E4-CC78DE4A96E4Q34469575-A6E82E4E-2A43-413A-B7A5-C0E29546CE9BQ35078238-E3363EA9-588A-46D0-912E-4E2177F7168AQ35082710-7012D8EC-E6F7-45C3-9965-25879D992D86Q35209364-378CE30D-D6B0-48EE-813A-05861F9B27F3Q35591514-A4887159-894A-48E5-86DE-1FD6526A774EQ35616060-BDD946B8-5AEA-4DBD-ACCC-9179996453BEQ35743123-302D1EEC-014C-415B-A15B-D2F88CFDBC2EQ35743127-E92D78E9-A1A3-4FC5-97FF-CD7F3160F590Q35743149-7E67D908-F86A-49F7-89E9-E6C76E59A358Q35831981-DFE08DD0-2440-49C6-9992-1FFD8CCDB191Q36017772-3D025B34-692A-45FC-A75B-8F6927FB11D2Q36139561-D35646ED-A9CA-44B0-AAE2-C56ABB8FE1F3Q36217894-168AE162-5E46-42B8-955C-983D7817C195Q36274969-A10C3F81-6E95-470E-BFF2-F392621BA1CAQ36316659-E2E2EAD9-CD32-4FF0-B38B-7ACC3E0A73EAQ36501732-DE1095D1-C1F1-413C-B734-DBFBFE4B61B9Q36934716-A698DDD9-CDA9-41D7-A1C0-4177C8F6CF4DQ36950485-7D575B2D-A79B-4537-8A5E-4F83E1E5AAD7Q37008849-5F47A567-FA0F-4F67-8AC4-0AD5F49CF827Q37021699-2193F60C-5C54-48EB-AAD7-4CC3D64147ADQ37176751-90977970-4161-4A99-86DD-548EED5A8E13Q37179796-D89795C0-B421-4589-9CAB-7D4E3AB04787Q37209606-552F30A7-8970-4593-B574-81820B9286FFQ37260295-5F7E3504-A35D-484B-B75B-1ADC1B8D7AF5Q37302745-4D5DBCBE-E5D5-48A6-8F43-98E429D1C881
P2860
Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Synthetic Smac/DIABLO peptides ...... inding XIAP and cIAP1 in situ.
@en
Synthetic Smac/DIABLO peptides ...... inding XIAP and cIAP1 in situ.
@nl
type
label
Synthetic Smac/DIABLO peptides ...... inding XIAP and cIAP1 in situ.
@en
Synthetic Smac/DIABLO peptides ...... inding XIAP and cIAP1 in situ.
@nl
prefLabel
Synthetic Smac/DIABLO peptides ...... inding XIAP and cIAP1 in situ.
@en
Synthetic Smac/DIABLO peptides ...... inding XIAP and cIAP1 in situ.
@nl
P2093
P2860
P356
P1476
Synthetic Smac/DIABLO peptides ...... inding XIAP and cIAP1 in situ.
@en
P2093
Christina R Arnt
Michael P Heldebrant
Mihnea V Chiorean
P2860
P304
44236-44243
P356
10.1074/JBC.M207578200
P407
P577
2002-09-05T00:00:00Z